NF1 Clinical Trial
Official title:
Natural History of Plexiform in Neurofibromatosis Type I
Background:
-Plexiform neurofibromas in patients with NF1 are a significant cause of morbidity but little
is known about the natural history of these lesions.
Objectives:
- The purpose of this study is to monitor the natural history of plexiform neurofibromas
and to evaluate the usefulness of volumetric MRI tumor measurements in this disease.
- Other goals of the study are to provide a body of normative data on the growth rate of
plexiform neurofibromas and to establish a tissue repository and pathology review center
to allow future studies of the pathogenesis of neurofibromas and clinical trials of
potential therapeutic agents.
Design
- This study is coordinated by Dr. Bruce Korf, and was initiated when he was at the Partners
Center for Human Genetics, Boston, MA.
Background:
-Plexiform neurofibromas in patients with NF1 are a significant cause of morbidity but little
is known about the natural history of these lesions.
Objectives:
- The purpose of this study is to monitor the natural history of plexiform neurofibromas
and to evaluate the usefulness of volumetric MRI tumor measurements in this disease.
- Other goals of the study are to provide a body of normative data on the growth rate of
plexiform neurofibromas and to establish a tissue repository and pathology review center
to allow future studies of the pathogenesis of neurofibromas and clinical trials of
potential therapeutic agents.
Design
- This study is coordinated by Dr. Bruce Korf, and was initiated when he was at the Partners
Center for Human Genetics, Boston, MA.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01362803 -
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06104488 -
A Study of Avutometinib for People With Solid Tumor Cancers
|
Phase 1 | |
Recruiting |
NCT02964884 -
Interventions for Reading Disabilities in NF1
|
Phase 2 | |
Completed |
NCT00684398 -
Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I
|
||
Recruiting |
NCT05238909 -
Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1
|
||
Active, not recruiting |
NCT04954001 -
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
|
Phase 1/Phase 2 | |
Terminated |
NCT01402817 -
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
|
Phase 2 | |
Terminated |
NCT02718131 -
A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)
|
N/A | |
Completed |
NCT02101736 -
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
|
Phase 2 | |
Recruiting |
NCT05913037 -
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
|
Phase 3 | |
Completed |
NCT01275586 -
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
|
Early Phase 1 | |
Recruiting |
NCT06159166 -
Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05253131 -
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
|
Phase 2 | |
Recruiting |
NCT04544007 -
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
|
Phase 2 |